|
|
||||||||
Journal of Lipid Research, Vol 37, 1591-1600, Copyright © 1996 by Lipid Research, Inc.
B Halvorsen, I Brude, CA Drevon, J Nysom, L Ose, EN Christiansen and MS Nenseter
Homocysteine is an independent risk factor for cardiovascular diseases. The
mechanisms by which elevated plasma concentrations of homocysteine are
related to the pathogenesis of atherosclerosis are not fully understood. To
examine whether homocysteine is implicated in atherogenesis through the
modification of low density lipoprotein (LDL), the effect of homocysteine
on the oxidation of LDL was studied by three different oxidation systems.
Thus, LDL was subjected to Cu(2+)- catalyzed, azo compound-initiated, and
peripheral blood mononuclear cell-mediated oxidative modification. The
extent of modification was assessed by measuring the formation of
conjugated dienes, lipid peroxides, thiobarbituric acid-reactive
substances, and the relative electrophoretic mobility. Homocysteine at a
normal plasma concentration (6 microM) showed no effect, whereas a
concentration corresponding to moderate hyperhomocysteinemia (25 microM) or
to concentrations seen in homocystinuria patients (100, 250, and 500
microM) protected LDL from modification of the lipid as well as of the
protein moiety. One exception was observed: when the oxidation was
initiated by copper ions, homocysteine at concentrations 6 and 25 microM
stimulated the lipid peroxidation of LDL to a small, but statistically
significant extent. High concentrations of homocysteine showed
antioxidative properties as long as the thiol groups were intact, thereby
delaying the onset of the oxidation. The 1,1-diphenyl-2-picrylhydracyl
radical test demonstrated that homocysteine at concentrations > or = 50
microM possessed marked free radical scavenging capacity. Finally, LDL
isolated from two patients with homozygous homocystinuria showed similar
extent of Cu(2+)-catalyzed oxidation as LDL from a group of healthy control
subjects. Taken together, our data suggest that low concentrations of
homocysteine in the presence of copper ions may enhance the lipid
peroxidation of LDL, whereas high concentrations of homocysteine may
protect LDL against oxidative modification in the lipid as well as in the
protein moiety. Thus, homocysteine-induced atherosclerosis may be explained
by mechanisms other than oxidative modification of low density lipoprotein.
ARTICLES
Effect of homocysteine on copper ion-catalyzed, azo compound-initiated, and mononuclear cell-mediated oxidative modification of low density lipoprotein
Institute for Nutrition Research, University of Oslo, Blindern, Norway.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
C. Carrasco-Pozo, A. Alvarez-Lueje, C. Olea-Azar, C. Lopez-Alarcon, and H. Speisky In vitro interaction between homocysteine and copper ions: potential redox implications. Experimental Biology and Medicine, October 1, 2006; 231(9): 1569 - 1575. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Atkin, A. Gasper, R. Ullegaddi, and H. J. Powers Oxidative Susceptibility of Unfractionated Serum or Plasma: Response to Antioxidants in Vitro and to Antioxidant Supplementation Clin. Chem., November 1, 2005; 51(11): 2138 - 2144. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. BESSEDE, C. MIGUET, P. GAMBERT, D. NEEL, and G. LIZARD Efficiency of homocysteine plus copper in inducing apoptosis is inversely proportional to {gamma}-glutamyl transpeptidase activity FASEB J, September 1, 2001; 15(11): 1927 - 1940. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. A. Ploplis, I. Cornelissen, M. J. Sandoval-Cooper, L. Weeks, F. A. Noria, and F. J. Castellino Remodeling of the Vessel Wall after Copper-Induced Injury Is Highly Attenuated in Mice with a Total Deficiency of Plasminogen Activator Inhibitor-1 Am. J. Pathol., January 1, 2001; 158(1): 107 - 117. [Abstract] [Full Text] [PDF] |
||||
![]() |
J Thambyrajah and J.N Townend Homocysteine and atherothrombosis--mechanisms for injury Eur. Heart J., June 2, 2000; 21(12): 967 - 974. [PDF] |
||||
![]() |
M. A. Mansoor, C. Bergmark, S. J. Haswell, I. F. Savage, P. H. Evans, R. K. Berge, A. M. Svardal, and O. Kristensen Correlation between Plasma Total Homocysteine and Copper in Patients with Peripheral Vascular Disease Clin. Chem., March 1, 2000; 46(3): 385 - 391. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Fonseca, S. C. Guba, and L. M. Fink Hyperhomocysteinemia and the Endocrine System: Implications for Atherosclerosis and Thrombosis Endocr. Rev., October 1, 1999; 20(5): 738 - 759. [Abstract] [Full Text] |
||||
![]() |
J. W. Eikelboom, E. Lonn, J. Genest Jr., G. Hankey, and S. Yusuf Homocyst(e)ine and Cardiovascular Disease: A Critical Review of the Epidemiologic Evidence Ann Intern Med, September 7, 1999; 131(5): 363 - 375. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Ferguson, S. Parthasarathy, J. Joseph, and B. Kalyanaraman Generation and initial characterization of a novel polyclonal antibody directed against homocysteine thiolactone-modified low density lipoprotein J. Lipid Res., April 1, 1998; 39(4): 925 - 933. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |